Dr. Neil Ettinger, MD
Pulmonology (Pulmonary Disease Physician)
222 S Woods Mill Rd, Suite 310n
Chesterfield, MO 63017
Who else practices at this address →
St. Louis County includes dental (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Washington University School of Medicine (1983)
- Years since graduation
- 43
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,114
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1983Medical school: Washington University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
MO license R8E82 -
Critical Care Medicine (Internal Medicine) Physician
MO license R8E82
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Barnes Jewish Hospital Saint Louis, MO
- St Lukes Hospital Chesterfield, MO
Medical groups
- Physician Specialists of St Lukes LLC (82 clinicians)
- Cardio-Pulmonary Associates, LLC (5 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,114
- Services billed
- 3,819
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 1,068 | 269 |
| Established patient office or other outpatient visit, 30-39 minutes | 890 | 518 |
| Established patient office or other outpatient visit, 20-29 minutes | 355 | 275 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 251 | 211 |
| Test to measure expiratory airflow and volume | 235 | 225 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 185 | 107 |
| Test to examine how well the lungs exchange gases | 170 | 166 |
| Test to determine lung volumes using sensors | 169 | 165 |
| New patient office or other outpatient visit, 45-59 minutes | 162 | 162 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 126 | 122 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Chesterfield, MO | 914 |
| Azithromycin Other prescribers in Chesterfield, MO | 578 |
| Prednisone Other prescribers in Chesterfield, MO | 525 |
| Ipratropium Bromide Other prescribers in Chesterfield, MO | 457 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Chesterfield, MO | 325 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Chesterfield, MO | 229 |
| Ofev (nintedanib esylate) | 197 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Chesterfield, MO | 106 |
| Roflumilast Other prescribers in Chesterfield, MO | 102 |
| Pirfenidone | 100 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 126 payments worth $9,705 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $7,356 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $542 |
| GlaxoSmithKline, LLC. | $341 |
| Baxter Healthcare | $182 |
| Insmed, Inc. | $148 |
| Merck Sharp & Dohme LLC | $145 |
| Regeneron Healthcare Solutions, Inc. | $137 |
| Actelion Pharmaceuticals US, Inc. | $105 |
| Compensation for services other than consulting (speaking, faculty) | $6,960 |
|---|---|
| Food and Beverage | $2,714 |
| Education | $31.05 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Jan 17, 2025 | Compensation for services other than consulting (speaking, faculty) OFEV · RESPIRATORY | $2,320 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Sep 4, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,320 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Sep 4, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,320 |
| Insmed, Inc. Jun 18, 2025 | Education in-kind | $17.38 |
| Merck Sharp & Dohme LLC Jun 26, 2025 | Education ZERBAXA · INFECTIOUS DISEASE · in-kind | $10.85 |
| Regeneron Healthcare Solutions, Inc. May 14, 2025 | Education DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind | $2.82 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 23 industry-funded studies in 2025, from 7 companies. The companies reported $561,759 in research payments for these studies, mostly to the institutions running them.
- A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibro…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
E.r. Squibb & Sons, L.l.c. - Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
United Therapeutics Corporation · Enrolling by invitation · NCT04905693 - An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON)
Boehringer Ingelheim Pharmaceuticals, Inc. - Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
United Therapeutics Corporation · Completed · NCT04708782 - A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim Pharmaceuticals, Inc. - Ph III OLE of Astegolimab in COPD
Genentech, Inc. - A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulm…
AstraZeneca Pharmaceuticals LP - Ph IIb of Astegolimab in COPD
Genentech, Inc. - A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.